# US 8,785,186 B2 · Hybrid cells for treating cancer patients > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,785,186 B2 - Document ID: US8785186B2 - Status: Granted - Kind: B2 - Application number: 12/461,760 - Filed: 2009-08-24 - Published: 2010-02-25 - Granted: 2014-07-22 - Earliest claimed: 2000-01-11 - Assignees: Orbis Health Solutions LLC - Applicants: Thomas E. Wagner; Yanzhang Wei - Inventors: Thomas E. Wagner; Yanzhang Wei - Web page: https://patentgrep.com/patent/US8785186B2 ## CPC - A61K 39/0011: {Cancer antigens} - A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00) - A61K 35/15: Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (presenting a specific antigen A61K39/00; therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K39/00) - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance} - A61K 40/19: Dendritic cells - A61K 40/24: Antigen-presenting cells [APC] - A61K 40/42: Cancer antigens - A61P 35/00: Antineoplastic agents - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - C12N 5/16: Animal cells - C12N 5/163: {one of the fusion partners being a B or a T lymphocyte} - A61K 2035/122: {for inducing tolerance or supression of immune responses} - A61K 2039/545: {characterised by the dose, timing or administration schedule} - A61K 2039/55594: {from bacteria} - A61K 2039/80: {Vaccine for a specifically defined cancer} - A61K 2239/31: characterized by the route of administration - A61K 2239/38: characterised by the dose, timing or administration schedule - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation. ## Claims ### Claim 1 A composition comprising a hybrid cell preparation, wherein the hybrid cell preparation is prepared by a method comprising: (a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first marker, (b) staining a dendritic cell population with a second marker, wherein the first marker is different from the second marker, (c) contacting the neoplastic cell population and the dendritic cell population with one another under conditions that promote cell fusion, (d) obtaining a resultant hybrid cell population stained with both the first and second markers, and (e) purifying the resultant hybrid cell population; wherein the method does not involve antibiotic or metabolic selection, the purifying is accomplished in less than about 24 to 48 hours after said contacting. ### Claim 2 (depends on 1) The composition of claim 1, wherein the first marker is a fluorescent dye, the second marker is a fluorescent dye, and the resultant hybrid cell population is purified by fluorescence activated cell sorting. ### Claim 3 (depends on 1) The composition of claim 1, wherein less than 10% of the resultant hybrid cell population is reactant cells. ### Claim 4 (depends on 1) The composition of claim 1, wherein less than 5% of the resultant hybrid cell population is reactant cells. ### Claim 5 (depends on 1) The composition of claim 1, further comprising a pharmaceutically acceptable vehicle. ### Claim 6 (depends on 2) The composition of claim 2, wherein the first and second fluorescent dyes are endotoxin-free, pyrogen-free or both. ### Claim 7 (depends on 1) The composition of claim 1, wherein the neoplastic cell is a tumor cell. ### Claim 8 (depends on 7) The composition of claim 7, wherein the tumor cell is a primary tumor cell. ### Claim 9 A method of treating cancer, comprising: (i) providing a hybrid cell preparation prepared by a method comprising: (a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first marker, (b) staining a dendritic cell population with a second marker, wherein the first marker is different from the second marker, (c) contacting said neoplastic cell population and the dendritic cell population with one another under conditions that promote cell fusion, (d) obtaining a resultant hybrid cell population stained with both the first and second markers, and (d) purifying the resultant hybrid cell population; wherein the method does not involve antibiotic or metabolic selection, said purifying is accomplished in less than about 24 to 48 hours after the contacting; (ii) resuspending the resultant hybrid cell preparation in a pharmaceutically acceptable vehicle, and (iii) administering the hybrid cell preparation to a cancer patient. ### Claim 10 (depends on 9) The method of claim 9, wherein the first marker is a fluorescent dye, the second marker is a fluorescent dye, and the resultant hybrid cell population is purified by fluorescence activated cell sorting. ### Claim 11 A cancer vaccine comprising a hybrid cell preparation and a pharmaceutically acceptable vehicle, wherein the hybrid cell preparation is prepared by a method comprising: (a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first marker, (b) staining a dendritic cell population with a second marker, wherein the first marker is different from the second marker, (c) contacting the neoplastic cell population and the dendritic cell population with one another under conditions that promote cell fusion, (d) obtaining a resultant hybrid cell population stained with both the first and second markers, (e) purifying the resultant hybrid cell population, and (f) resuspending the resultant hybrid cell population in a pharmaceutically acceptable vehicle; wherein the method does not involve antibiotic or metabolic selection, the purifying is accomplished in less than about 24 to 48 hours after the contacting. ### Claim 12 (depends on 11) The cancer vaccine of claim 11, wherein the first marker is a fluorescent dye, the second marker is a fluorescent dye, and the resultant hybrid cell population is purified by fluorescence activated cell sorting. ### Claim 13 (depends on 11) The cancer vaccine of claim 11, wherein the pharmaceutically acceptable vehicle is saline. ### Claim 14 A tumor vaccine comprising a hybrid cell preparation and a pharmaceutically acceptable vehicle, wherein the hybrid cell preparation is prepared by a method comprising: (a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first marker, (b) staining a dendritic cell population with a second marker, wherein the first marker is different from the second marker, (c) contacting the neoplastic cell population and the dendritic cell population with one another under conditions that promote cell fusion, (d) obtaining a resultant hybrid cell population stained with both the first and second markers, (e) purifying the resultant hybrid cell population, and (f) resuspending the resultant hybrid cell population in a pharmaceutically acceptable vehicle; wherein the method does not involve antibiotic or metabolic selection, the purifying is accomplished in less than about 24 to 48 hours after the contacting. ### Claim 15 (depends on 14) The tumor vaccine of claim 14, wherein the first marker is a fluorescent dye, the second marker is a fluorescent dye, and the resultant hybrid cell population is purified by fluorescence activated cell sorting. ### Claim 16 (depends on 14) The tumor vaccine of claim 14, wherein the pharmaceutically acceptable vehicle is saline. ### Claim 17 A kit comprising (i) at least two dyes that are essentially endotoxin-free or pyrogen-free or both; and (ii) instructions for preparing hybrid cells from reactant cells by a method comprising: (a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first dye from the at least two dyes, (b) staining a dendritic cell population with a second dye from the at least two dyes, wherein said first dye is different from said second dye, (c) contacting said neoplastic cell population and said dendritic cell population with one another under conditions that promote cell fusion, (d) obtaining a resultant hybrid cell population stained with both the first and second dyes, and (e) purifying the resultant hybrid cell population; wherein said method does not involve antibiotic or metabolic selection, said purifying is accomplished in less than about 24 to 48 hours after said contacting.